[Prevalence of asthma in Chilean students. Descriptive study of 24,470 children. ISAAC-Chile]. / Prevalencia del asma en escolares chilenos. Estudio descriptivo de 24.470 niños. ISAAC-Chile.

BACKGROUND: There is little information about the prevalence of asthma in Latin American children. AIM: To determine the prevalence of asthma among Chilean school age children. SUBJECTS AND METHODS: The prevalence of respiratory symptoms related to asthma in schoolchildren aged 7 and 13 years, coming from South Santiago, Central Santiago, Valdivia and Punta Arenas, was determined using the methodology of the International Study on Asthma and Allergies in Childhood (ISMC). A random sample of school children aged 6-7 and 13-14 years from each locality was selected. This resulted in 24)470 surveyed children (11,723 aged 6-7 years and 12,747 aged 13-14 years). RESULTS: The current prevalence of wheezing ("wheezing in the last 12 months") ranged from 16.5% to 20.0% in children aged 67 years, and from 6.8% to 11.7% in children aged 13-14 years. The cumulative prevalence of asthma ("asthma ever"), ranged from 9.7% and 16.5% in the 6-7 years group and from 7.3% to 12.4% in those aged 13-14 years. CONCLUSIONS: This study found much higher figures for prevalence of respiratory symptoms related to asthma in school children than those previously reported in this country, with a significant variability between centers (p < 0.05). The prevalence of asthma in Chilean schoolchildren is as high and variable as that reported in industrialized countries.

[Hodgkin's disease in children. Modified COPP combined treatment and radiotherapy in advanced stages]. / Enfermedad de Hodgkin en el niño. Tratamiento combinado COPP modificado y radioterapia en estadios avanzados.

Twenty two children, under 15 years of age, from southern Chile's Tenth Region, with advanced stages of Hodgkin's disease (8 III-A, 6 III-B and 8 IV-B) were treated with chemotherapy (modified COPP protocol) and radiotherapy between 1976 and 1985 at Valdivia's Regional Hospital. Overall survival rate was 77.3% and disease-free survival rate was 64.5% after a follow-up period from 3 to 13 years (median 70 months). Five patients died during the first two years. One relapsed 10 years after beginning of therapy, but achieved a second complete remission. The survival rate in patients with lymphocytic depletion type (5 cases) was 20.0%, whereas that of the mixed cellularity type (14 cases) was 92.9% (p less than 0.01). No cases of second neoplasms related to chemotherapy and radiotherapy were seen in this series.